Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 1 client • 6 examiners • 3 art units • 0 of 7 (0%) have an AI response strategy ready
Clark+Elbing LLP - Revolution Medicines, Inc. is active in the Biotechnology & Pharmaceuticals technology area, currently managing 5 pending office actions. This client-specific work is a subset of the firm's 8984 career applications. The 5 pending office actions show the firm's ongoing commitment to this sector. The firm's total of 8984 career applications provides the context for their expertise in Biotechnology & Pharmaceuticals.
A resolved allowance rate of 67.87 percent is maintained by the firm, based on its 8984 career applications. This 67.87 percent rate is a key performance metric for their patent prosecution services. The firm averages 3.89 office actions per allowance, which informs the expected prosecution path for new filings. Practitioners can use this 3.89 average to plan for the number of examiner interactions. With 5 pending office actions, the firm continues to apply its 67.87 percent allowance rate and 3.89 office action average to its current docket. These figures summarize the firm's historical results and present workload.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (43%) |
| §112 only | 1 (14%) |
| Double-patenting only | 1 (14%) |
| Multi-statute (no §101) | 2 (29%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHANDRAKUMAR, NIZAL S | 2 | 72.7% | +18.3% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| SANCHEZ, JUSTIN CHRISTOPHER | 1 | 88.7% | +10.2% |
| CHAO, ALLEN | 1 | 55.6% | +0.0% |
| MCDOWELL, BRIAN E | 1 | 74.1% | +30.8% |
| LADD, CAROLYN LOUISE | 1 | 58.6% | +47.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18771135 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18479500 | METHODS FOR INHIBITING RAS | LADD, CAROLYN LOUISE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18011454 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | CHANDRAKUMAR, NIZAL S | 132d overdue |
| 19308717 | RAS INHIBITORS | RZECZYCKI, PHILLIP MATTHEW | — |
| 18795852 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | CHANDRAKUMAR, NIZAL S | — |
| 18771135 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | SANCHEZ, JUSTIN CHRISTOPHER | — |
| 18591721 | RAS INHIBITORS | MCDOWELL, BRIAN E | — |
| 18479500 | METHODS FOR INHIBITING RAS | LADD, CAROLYN LOUISE | — |
| Client (Assignee) | Pending OAs |
|---|---|
| Revolution Medicines, Inc. | 7 |
| Art Unit | Apps |
|---|---|
| 1625 | 2 |
| 1622 | 2 |
| 1624 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19308717 | RAS INHIBITORS | Revolution Medicines, Inc. | RZECZYCKI, PHILLIP MATTHEW | 1625 | DP | Non-Final OA | — | Pending | Aug 25, 2025 |
| 18795852 | METHODS OF TREATING A RAS PROTEIN-RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. | CHANDRAKUMAR, NIZAL S | §103Other | Non-Final OA | — | Pending | Aug 06, 2024 | |
| 18771135 | METHODS OF TREATING A RAS RELATED DISEASE OR DISORDER | Revolution Medicines, Inc. | SANCHEZ, JUSTIN CHRISTOPHER | §102§112Other | Non-Final OA | — | Pending | Jul 12, 2024 | |
| 18634246 | SYNTHESIS OF RAS INHIBITORS | Revolution Medicines, Inc. | CHAO, ALLEN | 1622 | §103 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18591721 | RAS INHIBITORS | Revolution Medicines, Inc. | MCDOWELL, BRIAN E | 1624 | §112Other | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18479500 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. | LADD, CAROLYN LOUISE | 1622 | §102§112 | Non-Final OA | — | Pending | Oct 02, 2023 |
| 18011454 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | Revolution Medicines, Inc. | CHANDRAKUMAR, NIZAL S | 1625 | §103 | Final Rejection | 132d overdue | Pending | Dec 19, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial